

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEPrior application: Examiner L. StocktonArt Unit 1626Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR § 1.53(b), of pending prior U.S. Application No. 09/910,950, filed July 23, 2001, which claims the benefit of U.S. Provisional Application No. 60/221,799, filed July 31, 2000, the disclosure of each is incorporated by reference in the present application in its entirety.

Shripad S. Bhagwat; Yoshitaka Satoh; Steven Sakata; Christopher Buhr; Ronald Albers; John Sapienza;
of Veronique Plantevin; Qi Chao; Kiran Sahasrabudhe; Rachel Ferri

(inventor(s) currently of record in prior application)

INDAZOLE DERIVATIVES AS JNK INHIBITORS AND COMPOSITIONS AND METHODS RELATED
for THERETO

(title of invention)

1. ☒ The filing fee is calculated below:

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	87	- 20	67	\$18.00 each	\$ 1206.00
Independent	3	- 3	0	\$86.00 each	\$ 0.00
Minimum Fee					\$ 750.00
Multiple Dependency Fee					
If Applicable (\$280.00)					\$ 0.00
Total					\$ 1956.00
Applicant qualifies for the 50% Reduction for Independent					
Inventor, Nonprofit Organization or Small Business Concern					\$ 0.00
Total Filing Fee					\$ 1956.00

2. ☒ Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this document is enclosed.
3. ☐ Amend the specification by inserting before the first line the following sentence: This is a continuation of application no. filed which is incorporated by reference herein in its entirety.
- 4a. ☐ Drawings are enclosed.
- 4b. ☐ Informal drawings are enclosed.

- 5a. ☐ Priority of application no. filed on in is claimed under 35 U.S.C. §119.
- 5b. ☐ The certified copy has been filed in prior application no. , filed .
6. ☒ The prior application is assigned of record from Shripad S. Bhagwat; Yoshitaka Satoh; Steven Sakata; Ronald Albers; John Sapienza; Veronique Plantevin; Qi Chao; Kiran Sahasrabudhe; and Rachel Ferri to Signal Pharmaceuticals, Inc. (Reel/Frame 012692/0030) and is also assigned of record from Chris Buhr to Signal Pharmaceuticals, Inc. (Reel/Frame 012680/0489)
- 7a. ☒ A copy of the Declaration for Non-Provisional Patent Application (two counterparts) filed in the prior application no. no. 09/910,950 filed on July 23, 2001, is enclosed.
- 7b. ☐ Power of Attorney
8. ☐ This application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior application no., filed on be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from application no. is enclosed.
9. ☐ The undersigned states, under 37 C.F.R. §1.821(f), that the content of the enclosed paper Sequence Listing from application no. is the same as the content of the computer readable form submitted in application no. .
10. ☐ DO NOT PUBLISH. I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).
11. ☒ Additional Enclosures: Information Disclosure Statement; Form PTO-1449 listing references AA-BS; a copy of references AD and AE.

Respectfully submitted,

Date September 26, 2003

Anthony M. Insogna, N.Y. No. 35,203
By: Matthew E. Long, N.Y. No. 36,343
 35,203
 Anthony M. Insogna
 PENNIE & EDMONDS LLP
 1155 Avenue of the Americas
 New York, New York 10036-2711
 (212) 790-9090
 (Reg. No.)